Results 101 to 110 of about 23,403 (218)

Augmenting erythropoiesis using recombinant human erythropoietin at sea level blunts the high altitude induced increase in erythropoiesis

The Journal of Physiology, EarlyView.
Abstract figure legend Pharmacologically augmenting erythropoiesis with rEPO at sea level blunts the high altitude induced erythropoiesis. Abstract Erythropoiesis increases with high altitude (HA) acclimatization. Recombinant human erythropoietin (rEPO) induces erythropoiesis.
Roy M. Salgado, Thomas A. Mayer, Gabrielle E. W. Giersch, Billie K. Alba, David E. Barney Jr, Aaron R. Caldwell, Nisha Charkoudian, Brandon M. Roberts, Afton D. Seeley, K. Riley Connor, Andrew M. Greenfield, Adam J. Luippold, Mark L. Plamper, Jermaine A. Ward, Shauna M. Ward, Benjamin J. Ryan   +15 more
wiley   +1 more source

Caenorhabditis elegans as an in vivo model system for human inherited primary arrhythmia syndromes

The Journal of Physiology, EarlyView.
Abstract figure legend Most genes involved in inherited primary arrhythmia syndromes (IPAS) are conserved in Caenorhabditis elegans, where genetic manipulation enables functional characterization of variants, identification of regulatory proteins, and in vivo drug testing.
Antoine Delinière, Thomas Boulin, Maëlle Jospin, Alexandre Janin, Gilles Millat, Philippe Chevalier, Olga Andrini   +6 more
wiley   +1 more source

Unveiling the role of the venous system in arterial hypertension: A computational study

The Journal of Physiology, EarlyView.
Abstract figure legend This abstract figure summarizes the principal findings of our computational analysis of hypertension. Model‐based results identify reduced venous compliance as a major determinant of elevated arterial pressure, second only to increased peripheral resistance.
Eleuterio F. Toro, Lucas O. Müller, Tonja W. Emans, Fiona D. McBryde, Julian F. R. Paton   +4 more
wiley   +1 more source

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Tirzepatide and SGLT2 inhibitors act through distinct but complementary mechanisms in obesity‐related HFpEF: tirzepatide targets adiposity, inflammation, and insulin resistance, while SGLT2 inhibitors improve decongestion, myocardial energetics, and cardiac remodeling.
Zakariye Isak Mohamed, Abdinasir Adam Shidane, Abdullahi Mohamud Abdiasis, Mohamed Hassan Hussein, Ayaanle Osman Ibrahim, Anas Ali Abdi, Kowthar Ismail Hashi, Mohamed Abdullahi Mohamud, Ali Jimale Mohamed   +8 more
wiley   +1 more source

Novel Intranasal Loop Diuretic

JACC: Basic to Translational Science, 2023
Benjamin Esque, Eric D. Adler, Daniel Bensimhon   +2 more
openaire   +2 more sources

QTc Interval Prolongation and Associated Drug Therapy in Hospitalized Older Adults

Journal of the American Geriatrics Society, EarlyView.
Francesco Fantin, Sara Fiorini, Anna Giani, Luana Giacobbe, Elena Zoico, Gianluca Trifirò, Rocco Micciolo, Mauro Zamboni   +7 more
wiley   +1 more source

Molecular Mechanisms of Food Bioactive Constituents in the Management of Obesity and Hypertension: A Critical Review

Phytochemicals in Food and Medicine, Volume 1, Issue 3, September 2026.
Obesity and hypertension co‐exist and share molecular mechanisms in terms of dietary therapy, modulated by food bioactive constituents. ABSTRACT Obesity and hypertension are among the most pressing global public health challenges. They frequently co‐exist, with obesity‐related hypertension accounting for an estimated 75% of the hypertension burden ...
Samuel Oluwasegun Maccarthy, Emmanuel Anyachukwu Irondi, Abdulazeez Olamilekan Elemosho, Emmanuel Oladipo Ajani   +3 more
wiley   +1 more source

Use of loop diuretics in patients with chronic heart failure: an observational overview. [PDF]

Open Heart, 2023
Scholte NT, Aydin D, Linssen GC, Koudstaal S, Rademaker PC, Geerlings PR, van Gent MW, Aksoy I, Oosterom L, Boersma E, Brunner-La Rocca HP, Brugts JJ.   +11 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Increasing the reporting of adverse drug reaction‐related hospitalizations using an ICD‐10‐based identification workflow: A multicentre study from Switzerland

British Journal of Clinical Pharmacology, Volume 92, Issue 8, Page 2937-2948, August 2026.
Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber, Sophie‐Charlotte Bartel, Michael Boch, Christoph Rosen, Michael Bodmer, Balthasar Luzius Hug, Thomas Stammschulte, Patrick E. Beeler   +7 more
wiley   +1 more source